Tidal Investments LLC Lowers Position in Fresenius Medical Care AG (NYSE:FMS)

Tidal Investments LLC trimmed its position in Fresenius Medical Care AG (NYSE:FMS) by 2.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,385 shares of the company’s stock after selling 451 shares during the period. Tidal Investments LLC’s holdings in Fresenius Medical Care were worth $349,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in FMS. Creative Planning boosted its stake in Fresenius Medical Care by 18.9% in the 2nd quarter. Creative Planning now owns 40,140 shares of the company’s stock worth $766,000 after purchasing an additional 6,373 shares in the last quarter. Verition Fund Management LLC bought a new position in Fresenius Medical Care in the 3rd quarter valued at approximately $237,000. Wulff Hansen & CO. boosted its stake in Fresenius Medical Care by 1,809.0% during the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after purchasing an additional 325,439 shares during the last quarter. Quantinno Capital Management LP increased its holdings in shares of Fresenius Medical Care by 78.9% in the 3rd quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock worth $2,345,000 after purchasing an additional 48,554 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Fresenius Medical Care by 11.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 22,161 shares of the company’s stock worth $472,000 after purchasing an additional 2,233 shares during the last quarter. Institutional investors own 8.37% of the company’s stock.

Wall Street Analyst Weigh In

FMS has been the topic of several recent analyst reports. Berenberg Bank began coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective on the stock. Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. StockNews.com started coverage on shares of Fresenius Medical Care in a research report on Thursday, November 28th. They set a “strong-buy” rating on the stock. Finally, Truist Financial boosted their target price on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research note on Monday, October 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Fresenius Medical Care presently has a consensus rating of “Hold” and an average price target of $24.30.

Fresenius Medical Care Price Performance

Shares of NYSE:FMS opened at $22.71 on Wednesday. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $13.33 billion, a PE ratio of 18.77, a price-to-earnings-growth ratio of 0.96 and a beta of 0.93. The firm’s 50 day moving average price is $21.88 and its 200-day moving average price is $20.54. Fresenius Medical Care AG has a twelve month low of $17.93 and a twelve month high of $24.31.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.